Showing results (3071-3080 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|June 8, 2024
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinomaDomenico Mallardo, Francesca Sparano, Maria Grazia Vitale, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapyShaoxian Wu, Hongwei Jiang, Zhang Fang, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor modelsJiaojiao Luo, Wanyi Ng, Yangli Liu, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patientsWeimin Caii, Xiao Wu, Kun Guo, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapyZehao Zheng, Jie Mei, Renguo Guan, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapyJustyna Czapla, Alina Drzyzga, Joanna Ciepła, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsetsAqing Liu, Guan Zhang, Yanjie Yang, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2024
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort studyTatsuki Ikoma, Toshihiko Matsumoto, Shogen Boku, et al.
Pageof 652